http://www.diamyd.com/ Latest Press Releases and Financial Reports from Diamyd Medical. Copyright 2012. All rights reserved. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635760 En artikel med resultaten från Diamyd Medicals europeiska fas III-studie med den antigenbaserade diabetesterapin Diamyd® har publicerats i den vetenskapliga tidskriften the New England Journal of Medicine. De nu publicerade resultaten har tidigare presenterats på diabeteskonferensen "American... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635760 Thu, 02 Feb 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635761 An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635761 Thu, 02 Feb 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633640 Delårsrapport Diamyd Medical AB (publ), räkenskapsåret 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633640 Wed, 25 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633641 Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633641 Wed, 25 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629530 Totalt 50 barn från fyra års ålder med hög risk att utveckla typ 1-diabetes har inkluderats i en forskarinitierad fas II-studie, DiAPREV-IT, med Diamyd Medicals diabetesvaccin Diamyd® och studien är därmed fullrekryterad. Syftet med studien är att utvärdera om förebyggande behandling med Diamyd® kan... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629530 Mon, 09 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629531 A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd®. The study is thus fully recruited. The purpose of the study is to evaluate whether... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629531 Mon, 09 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624548 Q1 . Results from Phase I study in cancer pain shows promising safety data and relief of chronic pain Q2 . Recruitment for US Phase III study in type 1 diabetes is completed . Phase II study in cancer pain is started . University of Florida Research Foundation initiates court case against Diamyd... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624548 Thu, 08 Dec 2011 18:42:23 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624230 Vid Diamyd Medicals ordinarie bolagsstämma den 7 december meddelade vd Peter Zerhouni att det gångna året har varit händelserikt och omskakande, men att bolaget nu står väl rustat att fortsätta utveckla innovativa läkemedel för sjukdomar som idag saknar effektiva behandlingsalternativ. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624230 Wed, 07 Dec 2011 19:18:12 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624231 At Diamyd Medical's Annual General Meeting on December 7, Peter Zerhouni, President and CEO, commented that the past year had been eventful and turbulent, but that the Company now stands well-equipped to continue its efforts to develop innovative pharmaceuticals for diseases for which there are... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624231 Wed, 07 Dec 2011 19:18:12 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617953 University of Florida Research Foundation, Incorporated ("UFRF") och Diamyd Medical AB meddelar idag gemensamt att de nått en förlikning avseende den stämningsansökan som UFRF inkom med till United States Federal District Court i Florida, USA, mot Diamyd Medical i januari 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617953 Thu, 17 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617954 University of Florida Research Foundation, Incorporated ("UFRF"), and Diamyd Medical AB today jointly announced that they have settled the breach of contract litigation that UFRF filed in the United States Federal District Court in Florida against Diamyd Medical in January 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617954 Thu, 17 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617598 ÅRET I KORTHET Q1   . Resultat från fas I-studie i cancersmärta visar lovande säkerhetsdata och lindring avlångvarig smärta Q2   . Rekrytering fullbordas till amerikansk fas III-studie i typ 1-diabetes . Fas II-studie i cancersmärta startas . University of Florida Research Foundation inleder... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617598 Wed, 16 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615110 Följande kallelse till årsstämma kommer att hållas tillgänglig på Diamyd Medicals hemsida www.diamyd.com från och med onsdag den 9 november 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615110 Mon, 07 Nov 2011 19:31:13 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615111 The follwing summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Wednesday November 9, 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615111 Mon, 07 Nov 2011 19:31:13 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608334 Bokslutskommuniké Stockholm 13 oktober 2011 1 september 2010 - 31 augusti 2011 Bokslutskommuniké Diamyd Medical AB (publ.), räkenskapsåret 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608334 Thu, 13 Oct 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608335 Year End Report, Stockholm, October 13, 2011 September 1, 2010 - August 31, 2011 Fourth quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608335 Thu, 13 Oct 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599534 Diamyd Medical AB med samarbetspartners har fått ett forskningsanslag på tre miljoner dollar från amerikanska National Institutes of Health för att utveckla bolagets patenterade Nerve Targeting Drug Delivery System (NTDDS) för prevention av kemoterapi-inducerad perifer neuropati. Anslaget ger Diamyd... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599534 Mon, 12 Sep 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599535 Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599535 Mon, 12 Sep 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=593251 Diamyd Medical AB koncentrerar sina resurser på bolagets läkemedelskandidater för behandling av smärta och sjukdomar i nervsystemet. Avvecklingen av fas III-programmet med diabetesterapin Diamyd® innebär avsevärt lägre kostnader för bolaget vilket skapar strategiskt handlingsutrymme. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=593251 Wed, 17 Aug 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=593252 Diamyd Medical AB is concentrating its resources on the Company's drug candidates for the treatment of pain and diseases of the nervous system. The termination of the Phase III program with the diabetes therapy Diamyd® means significantly lower costs for the Company which creates strategic leeway. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=593252 Wed, 17 Aug 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=587000 Diamyd Medicals styrelse har utsett Peter Zerhouni, tillförordnad VD i Diamyd Medical AB, till VD i bolaget. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=587000 Mon, 04 Jul 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=587001 The Board of Diamyd Medical has appointed Peter Zerhouni, Acting President of Diamyd Medical AB, as President of the Company. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=587001 Mon, 04 Jul 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586655 Delårsrapport Stockholm 1 juli 2011 1 september 2010 - 31 maj 2011 Delårsrapport 3 Diamyd Medical AB (publ.), räkenskapsåret 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Tredje kvartalet 1 mars 2011 - 31 maj 2011 · Koncernens nettoomsättning under tredje kvartalet... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586655 Fri, 01 Jul 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586656 Quarterly report, Stockholm, July 1, 2011 September 1, 2010 - May 31, 2011 Third quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Third quarter, March 1, 2011 - May 31, 2011 · Group net sales for the third quarter... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586656 Fri, 01 Jul 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586229 Diamyd Medical meddelar idag att bolagets konvertibla skuldebrev i det amerikanska vaccinbolaget Protein Sciences Corporation, har konverterats till aktier. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586229 Thu, 30 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586230 Diamyd Medical AB announced today that the Company's convertible promissory note in the US vaccine company Protein Sciences Corporation has been converted into shares. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=586230 Thu, 30 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585833 Diamyd Medical AB meddelar de detaljerade resultaten från bolagets europeiska fas III-studie med den antigenbaserade diabetesterapin Diamyd®, som inte uppnådde den primära effektparametern, vilket tidigare rapporterats. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585833 Tue, 28 Jun 2011 16:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585834 Diamyd Medical AB reports detailed results from the Company's European Phase III study of the antigen-based diabetes therapy Diamyd®, which, as previously announced, did not meet the primary efficacy endpoint. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585834 Tue, 28 Jun 2011 16:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585578 Diamyd Medical AB meddelar att resultaten av en studie med bolagets antigenbaserade diabetesterapi Diamyd® som genomförs av forskningskonsortiet "Type 1 Diabetes TrialNet" inte visade någon statistiskt signifikant effekt av studieläkemedlet. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585578 Tue, 28 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585579 Diamyd Medical AB reports that the results of a study with the Company's antigen-based diabetes therapy Diamyd®, conducted by the research consortium Type 1 Diabetes TrialNet did not show a statistically significant effect of the study drug. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=585579 Tue, 28 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=584434 Diamyd Medical AB meddelar att bolaget har beslutat att inte ge ytterligare injektioner av studieläkemedel i en amerikansk fas III-studie med den antigenbaserade terapin Diamyd® och att inleda stängning av studien. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=584434 Thu, 23 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=584435 Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd® and to initiate closure of the study. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=584435 Thu, 23 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578779 Diamyd Medical AB meddelar att bolaget har beslutat att inte slutföra uppföljningsperioden i en europeisk fas III-studie med den antigenbaserade terapin Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578779 Wed, 01 Jun 2011 08:31:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578780 Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578780 Wed, 01 Jun 2011 08:31:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578777 Diamyd Medical AB meddelar att bolaget har återfått kontrollen över diabetesterapin Diamyd® efter att Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), valt att avsluta det avtal som de två bolagen tecknade i juni 2010 för att utveckla och kommersialisera Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578777 Wed, 01 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578778 Diamyd Medical AB announces it has regained control of the diabetes therapy Diamyd® following Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) election to terminate the agreement the two companies signed in June 2010 to develop and commercialize Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=578778 Wed, 01 Jun 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=570261 Diamyd Medical AB meddelar att resultaten från bolagets europeiska fas III-studie med den antigenbaserade terapin Diamyd® inte uppfyllde den primära effektparametern att bevara betacellfunktion efter 15 månader, mätt som C-peptid, hos patienter som nyligen diagnostiserats med typ 1-diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=570261 Mon, 09 May 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=570262 Diamyd Medical AB reports that results from its European Phase III study with the antigen-based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=570262 Mon, 09 May 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=565895 Diamyd Medical AB meddelar att Elisabeth Lindner idag har lämnat sin befattning som VD och koncernchef för bolaget. Vice VD Peter Zerhouni har utnämnts till tillförordnad VD och koncernchef. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=565895 Tue, 26 Apr 2011 13:21:38 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=565896 Diamyd Medical AB announces that Elisabeth Lindner today has left her position as President and CEO of the Company. Excecutive Vice President Peter Zerhouni has been appointed Acting President and CEO. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=565896 Tue, 26 Apr 2011 13:21:38 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=564970 Peter Zerhouni, chef för affärsutveckling i Diamyd Medical AB, har utsetts till vice VD i bolaget. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=564970 Thu, 21 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=564971 Peter Zerhouni, Senior Director Business Development at Diamyd Medical AB, has been appointed Executive Vice President of the Company. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=564971 Thu, 21 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=562931 Delårsrapport Stockholm 14 april 2011 1 september 2010 - 28 februari 2011 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=562931 Thu, 14 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=562932 Quarterly report, Stockholm, April 14, 2011 September 1, 2010 - February 28, 2011 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=562932 Thu, 14 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=561819 Diamyd Medicals resultat från den fas I-studie som utvärderat säkerhet och effekt av läkemedelskandidaten NP2 Enkefalin, för behandling av svårbehandlad cancersmärta, har publicerats i den medicinska tidskriften Annals of Neurology. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=561819 Mon, 11 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=561820 Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=561820 Mon, 11 Apr 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=550334 Per den 28 februari 2011 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 789 566,50 kronor. Det totala antalet röster uppgår till 4 252 001 och det totala antalet aktier till 29 579 133, varav 1 437 876 aktier av serie A med en (1) röst vardera och 28 141 257 aktier av serie B med en... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=550334 Mon, 28 Feb 2011 18:00:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=550335 As of February 28, 2011, the share capital in Diamyd Medical AB (publ.) is 14,789,566.50 SEK. The total number of votes is 4,252,001 and the total number of shares is 29,579,133, divided among 1,437,876 shares of series A (1 vote) and 28,141,257 shares of series B (1/10 vote). The reason for this ad... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=550335 Mon, 28 Feb 2011 18:00:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=549982 Per den 28 februari 2011 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 764 706,50 kronor. Det totala antalet röster uppgår till 4 247 029 och det totala antalet aktier till 29 529 413, varav 1 437 876 aktier av serie A med en (1) röst vardera och 28 091 537 aktier av serie B med en... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=549982 Mon, 28 Feb 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=549983 As of February 28, 2011, the share capital in Diamyd Medical AB (publ.) is 14,764,706.50 SEK. The total number of votes is 4,247,029 and the total number of shares is 29,529,413, divided among 1,437,876 shares of series A (1 vote) and 28,091,537 shares of series B (1/10 vote). This change is due to... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=549983 Mon, 28 Feb 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546748 Den sista patienten har gjort sitt 15-månadersbesök i Diamyd Medicals europeiska fas III-studie. Behandling med den antigenbaserade läkemedelskandidaten Diamyd® görs för att utvärdera om det går att bevara betacellfunktionen och därigenom blodsockerkontrollen hos barn och ungdomar som nyligen fått... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546748 Mon, 14 Feb 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546750 The final patient has performed the last visit of the main study period in Diamyd Medical's European Phase III study. Treatment with the antigen based therapy Diamyd® is made to investigate whether beta cell function and thereby blood sugar control can be preserved in children and adolescents with... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546750 Mon, 14 Feb 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546557 University of Florida Research Foundation Inc. (UFRF) har inkommit med en stämningsansökan till United States Federal District Court i Florida mot Diamyd Medical, där UFRF yrkar rätt till en procentandel av den licensbetalning som erlagts till Diamyd Medical av Ortho-McNeil-Jansen Pharmaceuticals,... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546557 Fri, 11 Feb 2011 13:00:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546558 The University of Florida Research Foundation Inc. (UFRF) has filed a lawsuit in United States federal district court in Florida against Diamyd Medical claiming that UFRF is entitled to a percentage of the license fee paid to Diamyd Medical by Ortho-McNeil-Jansen Pharmaceuticals, Inc. (OMJPI).... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=546558 Fri, 11 Feb 2011 13:00:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=545745 Diamyd Medical´s US Phase II clinical trial, evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain, is posted on the ClinicalTrials.gov website. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=545745 Thu, 10 Feb 2011 09:48:55 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=545744 Diamyd Medicals amerikanska fas II-studie med syfte att testa läkemedelskandidaten NP2 Enkefalins potential att lindra cancersmärta har listats på webbplatsen ClinicalTrials.gov. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=545744 Thu, 10 Feb 2011 09:48:54 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538628 Diamyd Medicals vd och koncernchef Elisabeth Lindner meddelar i vd-ordet i dagens delårsrapport att resultat från bolagets europeiska fas III-studie i typ 1-diabetes beräknas börja rapporteras som planerat under senvåren 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538628 Tue, 25 Jan 2011 08:31:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538629 Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538629 Tue, 25 Jan 2011 08:31:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538624 Delårsrapport Stockholm 25 januari 2011 1 september 2010 - 30 november 2010 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538624 Tue, 25 Jan 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538625 Quarterly report, Stockholm, January 25, 2011 September 1, 2010 - November 30, 2010 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=538625 Tue, 25 Jan 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=537312 Diamyd Medical har behandlat den första deltagaren i en amerikansk klinisk fas II-studie som syftar till att utvärdera möjligheten att lindra cancersmärta med läkemedelskandidaten NP2 Enkefalin. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=537312 Mon, 17 Jan 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=537313 Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=537313 Mon, 17 Jan 2011 08:30:00 +0100